Business, energy, technology, markets and global industry news from Business News Today

Daiichi Sankyo

PharmaDeviceNews Daiichi Sankyo
Avacta’s upcoming AVA6103 clinical data will test whether its sustained-release exatecan therapy can concentrate cancer treatment inside tumours while limiting systemic exposure. Representative image.
Features & Analysis

Avacta previews AVA6103 pharmacokinetic data as sustained-release cancer drug faces first human test

Avacta’s next AVA6103 data will test sustained exatecan release in cancer patients. Read what the FOCUS-01 results could mean for its platform.

Read More
Representative image: Enhertu’s EU tumor-agnostic approval highlights how HER2 testing and precision oncology diagnostics could shape treatment access for advanced solid tumors.
Medical Devices & Diagnostics

Enhertu wins EU tumor-agnostic approval, but HER2 testing will decide its real impact

The European approval takes Enhertu beyond organ-specific oncology, although its clinical reach will depend on reliable HER2 testing, reimbursement and safety management.

Read More
CHMP backs Datroway in first-line TNBC
Pharma & Biotech

Datroway nears EU first-line approval for metastatic triple-negative breast cancer

Discover how Datroway’s EU recommendation could reshape first-line treatment for metastatic triple-negative breast cancer. Read the analysis.

Read More
Representative image: Enhertu’s EU recommendation could expand HER2 targeted cancer treatment options for patients with previously treated metastatic solid tumors, highlighting the growing role of antibody drug conjugates and precision oncology in advanced cancer care.
Pharma & Biotech

Enhertu nears wider EU approval as HER2 testing moves deeper into solid tumor oncology

Find out how Enhertu’s EU recommendation could reshape HER2 targeted treatment for metastatic solid tumors.

Read More
Representative image: A cancer patient receives infusion-based oncology care in a modern clinic, reflecting Datroway’s FDA approval as a new first-line treatment option for metastatic triple-negative breast cancer patients who are not eligible for immunotherapy.
Pharma & Biotech

AstraZeneca and Daiichi Sankyo deepen ADC ambitions with Datroway’s TNBC approval

Datroway challenges chemotherapy in first-line TNBC. AstraZeneca and Daiichi Sankyo now face the real test: adoption, safety and access.

Read More
Representative image: An oncologist reviews breast cancer imaging with a patient in a clinical setting, reflecting how AstraZeneca and Daiichi Sankyo’s ENHERTU approval could reshape treatment options for HER2-positive early breast cancer.
Pharma & Biotech

ENHERTU enters curative-intent breast cancer care as FDA widens AstraZeneca and Daiichi Sankyo label

ENHERTU is moving earlier in breast cancer care. The bigger question is whether efficacy gains can outweigh ADC safety scrutiny.

Read More
Pharma & Biotech

Why OnCusp Therapeutics’ CFO hire matters for its CDH6 antibody-drug conjugate strategy

CDH6 ADCs are heating up. OnCusp Therapeutics now needs capital discipline to turn CUSP06 promise into clinical and investor credibility.

Read More
Pharma & Biotech

Is Nuvation Bio building the next IDH1 glioma contender with safusidenib and SIGMA?

Nuvation Bio now controls safusidenib globally. Read why the Japan deal matters for IDH1-mutant glioma, SIGMA, and the post-vorasidenib market.

Read More
Pharma & Biotech

How Tempus AI and Daiichi Sankyo are using real-world data to reshape antibody-drug conjugate development

Tempus AI and Daiichi Sankyo are using multimodal AI to refine ADC trial strategy and biomarker discovery. Read what this could change next.

Read More
Pharma & Biotech

Avacta (AIM: AVCT) FAP-Exd data challenges Enhertu on tumor selectivity ahead of Phase 1 start

Avacta Therapeutics (AIM: AVCT) has published preclinical data showing that its FAP-targeted payload delivery platform, FAP-Exd (AVA6103), outperforms the marketed antibody drug conjugate trastuzumab deruxtecan across three pharmacokinetic measures, with a Phase 1 clinical trial expected to begin in the first quarter of 2026. What the AI-generated comparator actually enables The methodological choice here deserves

Read More